24/7 Wall St. on MSN6m
Can This Dividend King Ever Hit $400 After This Major Fail?AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback